ABOS · Acumen Pharmaceuticals, Inc.
$2.92
-0.11 (-3.63%)
At close · Aug 28
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on our current operating plan, we expect that our current balance of cash and cash equivalents and marketable securities will fund our operations into early 2027, but we believe it will not be enough to fund our operations for at least 12 months from the date of issuance of our financial statements included in this Quarterly Report on Form 10-Q. Our cash forecast contains estimates and assumptions related to our ongoing clinical trial and other research and development expenses, and we cannot predict the amount or timing of all expenditures with certainty. Accordingly, we have concluded that substantial doubt exists about our ability to continue as a going concern.”View the 10-Q filed Aug 12, 2026
Market Cap
$211.17M
Shares
72.32M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Net Income
-$121.34M
-18.6%
FY2025
Diluted EPS
-$2.00
-17%
FY2025
Operating Cash Flow
-$115.54M
-34%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| $86.79M | $104.89M | $93.8M | $42.32M | $32.36M | $12.31M | $8M | |
| $18.63M | $18.95M | $20.22M | $18.82M | $12.88M | $7.28M | $1.35M | |
| $105.42M | $123.83M | $114.02M | $61.14M | $45.24M | $19.58M | $9.35M | |
| -$105.42M | -$123.83M | -$114.02M | -$61.14M | -$45.24M | -$19.58M | -$7.91M | |
| $4.32M | $4.22M | $4.07M | $581K | $0 | — | — | |
| $5.14M | $7.45M | $14.32M | $10.79M | $2.39M | — | — | |
| $373K | $2.5M | $11.69M | $8.77M | $2.38M | -$81.02M | $587K | |
| — | $0 | $0 | $0 | $0 | $0 | $0 | |
| -$105.04M | -$121.34M | -$102.33M | -$52.37M | -$42.86M | -$100.61M | -$7.33M | |
| -$105.08M | -$121.2M | -$102.69M | -$51.31M | -$43.38M | -$100.84M | — | |
| USD/shares | -$1.62 | -$2.00 | -$1.71 | -$1.08 | -$1.06 | -$5.02 | — |
| USD/shares | -$1.62 | -$2.00 | -$1.71 | -$1.08 | -$1.06 | -$5.02 | — |
| shares | — | 60.56M | 60.01M | 48.61M | 40.6M | 20.06M | 419.12K |
| shares | — | 60.56M | 60.01M | 48.61M | 40.6M | 20.06M | 419.12K |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 4.36×
EV/EBIT
—
Peer median 9.59×
P/E (TTM)
—
Peer median 11.54×
Peer medians compare against the 308 similar-size Biotechnology companies (of 524 listed).
Key facts
CIK
1576885
CUSIP
00509G209
13F (30d)
84 filings
84 filers
Visit website
Investor relations